Pharma

Your Article Summary

See Latest Articles

Cell Therapeutics Completes Pixantrone NDA Submission and Requests Priority Review
Cell Therapeutics, 06/25/09

Cell Therapeutics, Inc. announced that it has completed the submission of the New Drug Application to the U.S. Food and Drug Administration for pixantrone to treat relapsed or refractory, aggressive non-Hodgkin's lymphoma. CTI requested priority review, which if granted could lead to an approval decision from the FDA in the fourth quarter of 2009. Pixantrone is currently available in Europe on a named-patient basis.

Today in Regulatory Issues...keeping you current

Receive free subspecialty "5-minute updates" via email

Avodart (dutasteride) Regulatory Update
GlaxoSmithKline, 10/02/09

Retigabine Regulatory Update
GlaxoSmithKline, 11/03/09

Beware of Tight 5010 Deadline
HealthDataManagement, 10/16/09

See All of Regulatory Issues